secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001477932-25-002574
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 3.03
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab Corp. effects 1-for-10 reverse stock split effective April 7, 2025
--------------------------------------------------------------------------------

- 1-for-10 reverse split effective 12:01 a.m. ET April 7, 2025; shares reduced from 17,967,663 to 1,796,597.
- No fractional shares issued; cash payment based on 10-day VWAP prior to effective date (corrects prior cash payment price).
- Reverse split aims to regain compliance with Nasdaq Minimum Bid Price Rule by May 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225002574/0001477932-25-002574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225002574/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-002574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer